OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
213858

EC Healthcare

Personal ServicesVerified

EC Healthcare maintains a capital structure with a debt-to-equity ratio of 0.75, indicating moderate leverage. The company holds HKD 1.0 billion in cash and equivalents, but its long-term debt of HKD 1.34 billion suggests a net cash position that is negative after subtracting total debt. Free cash flow of HKD 450 million supports liquidity, but the current ratio of 1.0 implies limited buffer against short-term obligations. Profitability metrics are weak, with a return on equity of -9.32% and a return on assets of -3.33%. These figures fall significantly below the industry median for healthcare services, which typically exhibit positive returns. The company reported a net loss of HKD 167 million, driven by a narrow operating income of HKD 84 million despite a gross profit of HKD 3.34 billion. The company's revenue is distributed across three segments: Medical Services, Aesthetic Medical and Beauty and Wellness, and Other. The Medical Services segment is the largest contributor, but the Aesthetic and Wellness segment is growing faster. Geographically, the company is concentrated in Hong Kong, with no material international revenue disclosed. This concentration increases exposure to local regulatory and economic shifts. Revenue growth has been modest, with the most recent reported revenue of HKD 4.14 billion. Analysts expect continued pressure on margins, with no clear path to profitability in the near term. Capital expenditures of HKD 57 million suggest limited reinvestment in core operations, which may hinder long-term growth. Risk factors include liquidity constraints and a negative net cash position. The company's dilution risk is currently low, but the risk assessment flags potential pressure from future capital needs. The company has not issued additional shares recently, and no dilutive events are currently scheduled. Recent filings and transcripts highlight ongoing cost management efforts and a focus on expanding the Aesthetic and Wellness segment. The company has not disclosed material new contracts or regulatory changes that would significantly alter its trajectory. Management has emphasized operational efficiency as a key priority.

30-day price · 2138-0.07 (-13.5%)
Low$0.40High$0.54Close$0.41As of21 May, 00:00 UTC
Profile
CompanyEC Healthcare
Ticker2138.HK
SectorConsumer Non-Cyclicals
BusinessPersonal & Household Products & Services
Industry groupPersonal & Household Products & Services
IndustryPersonal Services
AI analysis

Business. EC Healthcare operates as an investment holding company engaged in the provision of medical and healthcare services, including medical services, dental services, aesthetic medicine, beauty and wellness, and other ancillary services.

Classification. EC Healthcare is classified under the Consumer Non-Cyclicals economic sector, Personal & Household Products & Services business sector, and Personal Services industry, with a confidence level of 0.92.

EC Healthcare maintains a capital structure with a debt-to-equity ratio of 0.75, indicating moderate leverage. The company holds HKD 1.0 billion in cash and equivalents, but its long-term debt of HKD 1.34 billion suggests a net cash position that is negative after subtracting total debt. Free cash flow of HKD 450 million supports liquidity, but the current ratio of 1.0 implies limited buffer against short-term obligations. Profitability metrics are weak, with a return on equity of -9.32% and a return on assets of -3.33%. These figures fall significantly below the industry median for healthcare services, which typically exhibit positive returns. The company reported a net loss of HKD 167 million, driven by a narrow operating income of HKD 84 million despite a gross profit of HKD 3.34 billion. The company's revenue is distributed across three segments: Medical Services, Aesthetic Medical and Beauty and Wellness, and Other. The Medical Services segment is the largest contributor, but the Aesthetic and Wellness segment is growing faster. Geographically, the company is concentrated in Hong Kong, with no material international revenue disclosed. This concentration increases exposure to local regulatory and economic shifts. Revenue growth has been modest, with the most recent reported revenue of HKD 4.14 billion. Analysts expect continued pressure on margins, with no clear path to profitability in the near term. Capital expenditures of HKD 57 million suggest limited reinvestment in core operations, which may hinder long-term growth. Risk factors include liquidity constraints and a negative net cash position. The company's dilution risk is currently low, but the risk assessment flags potential pressure from future capital needs. The company has not issued additional shares recently, and no dilutive events are currently scheduled. Recent filings and transcripts highlight ongoing cost management efforts and a focus on expanding the Aesthetic and Wellness segment. The company has not disclosed material new contracts or regulatory changes that would significantly alter its trajectory. Management has emphasized operational efficiency as a key priority.
Key takeaways
  • EC Healthcare operates in a fragmented healthcare services market with weak profitability metrics.
  • The company's liquidity position is moderate, with free cash flow offsetting some debt obligations.
  • Revenue is concentrated in Hong Kong, increasing exposure to local economic and regulatory risks.
  • The Aesthetic and Wellness segment is a growth driver but has not yet translated into overall profitability.
  • Management is focused on cost control and segment expansion, but capital expenditures remain low.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyHKD
Revenue$4.14B
Gross profit$3.34B
Operating income$83.7M
Net income-$167.2M
R&D
SG&A
D&A
SBC
Operating cash flow$743.2M
CapEx-$57.2M
Free cash flow$450.0M
Total assets$5.03B
Total liabilities$3.23B
Total equity$1.79B
Cash & equivalents$1.00B
Long-term debt$1.34B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$4.14B$83.7M-$167.2M$450.0M
FY-1$4.21B$112.3M-$18.9M$424.3M
FY-2$3.88B$187.5M$69.7M$163.3M
FY-3$2.92B$371.0M$197.5M$170.6M
FY-4$2.08B$284.6M$192.9M$272.5M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$5.03B$1.79B$1.00B
FY-1$5.37B$1.96B$553.6M
FY-2$5.51B$1.85B$709.9M
FY-3$4.86B$1.88B$870.2M
FY-4$3.79B$1.27B$931.1M
PeriodOCFCapExFCFSBC
FY0$743.2M-$57.2M$450.0M
FY-1$689.1M-$161.2M$424.3M
FY-2$605.3M-$412.5M$163.3M
FY-3$608.4M-$260.3M$170.6M
FY-4$620.8M-$149.1M$272.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.79B
Net cash-$339.2M
Current ratio1.0
Debt/Equity0.8
ROA-3.3%
ROE-9.3%
Cash conversion-4.5%
CapEx/Revenue-1.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Personal Services · cohort 133 companies
Metric2138Activity
Op margin2.0%6.6% medp25 2.0% · p75 15.3%bottom quartile
Net margin-4.0%3.5% medp25 0.3% · p75 9.8%bottom quartile
Gross margin80.7%48.3% medp25 25.3% · p75 76.8%top quartile
CapEx / revenue-1.4%-3.2% medp25 -9.7% · p75 -1.3%above median
Debt / equity75.0%59.7% medp25 14.5% · p75 117.6%above median
Observations
IR observations
Last actual EPS-0.02 HKD
Last actual revenue4,211,034,000 HKD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 06:46 UTC#70b8589c
Market quoteclose HKD 0.46 · shares 1.19B diluted
no public URL
2026-05-04 05:43 UTC#997a0ddd
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 06:48 UTCJob: 0288c9ee